Who are Kariva®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Phase 3 NOMAC-E2 "Batch A", Drospirenone Ethinyl estradiol Myo-inositol, Nomegestrol Acetate / Estradiol, norelgestromin + ethinyl estradiol, Intermittent OC (EE/DROS), Ortho Tri-Cyclen LO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kariva.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Kariva® — Competitive Intelligence Brief

Kariva® (Kariva®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined hormonal contraceptive). Area: Contraception / Gynecology.

marketed Oral contraceptive (combined hormonal contraceptive) Progesterone receptor, estrogen receptor Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Kariva® (Kariva®) — Teva Branded Pharmaceutical Products R&D, Inc.. Kariva is an oral contraceptive that prevents pregnancy by suppressing ovulation through a combination of ethinyl estradiol and desogestrel.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Kariva® TARGET	Kariva®	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor
Phase 3 NOMAC-E2 "Batch A"	Phase 3 NOMAC-E2 "Batch A"	Organon and Co	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Drospirenone Ethinyl estradiol Myo-inositol	Drospirenone Ethinyl estradiol Myo-inositol	AGUNCO Obstetrics and Gynecology Centre	marketed	Oral contraceptive with insulin sensitizer	Progesterone receptor, estrogen receptor, inositol signaling pathway
Nomegestrol Acetate / Estradiol	Nomegestrol Acetate / Estradiol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, Estrogen receptor
norelgestromin + ethinyl estradiol	norelgestromin + ethinyl estradiol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Combined oral contraceptive (progestin + estrogen)	Progesterone receptor, estrogen receptor
Intermittent OC (EE/DROS)	Intermittent OC (EE/DROS)	University of North Carolina, Chapel Hill	marketed	Oral contraceptive	Progesterone receptor, estrogen receptor
Ortho Tri-Cyclen LO	Ortho Tri-Cyclen LO	Bristol-Myers Squibb	marketed	Oral contraceptive (combined hormonal contraceptive)	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined hormonal contraceptive) class)

Bayer · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Organon and Co · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
Virginia Commonwealth University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Kariva® — Competitive Intelligence Brief. https://druglandscape.com/ci/kariva. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab